Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2011-08-24 Annual Report
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
Preliminary Final Report 71 pages 808.6KB
Annual Report Classification · 95% confidence The document is titled 'Preliminary Final Report for the year ended 30 June 2011' and references an Appendix 4E, which is a standard Australian Stock Exchange (ASX) form for preliminary final reports. It contains detailed financial results for the full fiscal year, including net loss, revenue, cash flow, and other financial metrics. The document also includes extensive narrative on company progress, clinical trials, investments, and board appointments, which is typical of an annual report. The presence of audited or reviewed financial statements further supports this classification. The document length is substantial (15,000 characters), indicating it is the report itself, not just an announcement of a report. Therefore, this document fits the definition of an Annual Report (10-K equivalent). FY 2011
2011-08-24 English
First Argentina Patients Implanted 3 pages 44.5KB
Regulatory Filings Classification · 95% confidence The document is a company announcement from Living Cell Technologies Limited about the initiation of a Phase II clinical trial for their diabetes treatment product DIABECELL in Argentina. It discusses clinical trial progress, dosage strategies, and technology used, but does not contain financial data, regulatory filings, or detailed financial reports. It is a press release-style update on clinical development progress rather than a financial report, regulatory filing, or management discussion. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is an announcement of clinical trial progress and company development news, which is best classified under Regulatory Filings (RNS) as a general company announcement that does not fit other specific categories.
2011-08-21 English
Appendix 3B 7 pages 124.1KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new ordinary shares, including number of shares, issue price, purpose of the issue, and quotation application to the ASX (Australian Securities Exchange). It includes sections on securities issued, ranking, quotation agreement, and compliance with ASX rules. The document is a formal announcement of a new share issue and application for quotation of additional securities, consistent with regulatory filings for capital raising and securities issuance. It does not contain financial statements, management discussion, or audit information. It is not a report but an announcement related to capital structure changes and securities issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (9922 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2011-08-01 English
Cleansing Statement 1 page 28.8KB
Share Issue/Capital Change Classification · 95% confidence The document is a notice under Section 708A(5)(e) of the Corporations Act regarding the issuance of fully paid ordinary shares without disclosure under Part 6D.2 of the Corporations Act. It is a regulatory announcement about a share issue event, specifically notifying compliance with disclosure requirements and absence of excluded information. The document is short (1187 characters) and is a formal announcement rather than a detailed report or financial statement. This fits the category of Share Issue/Capital Change announcements, which cover new share issues and related disclosures.
2011-08-01 English
Appendix 4C - quarterly 7 pages 125.6KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly Cash Flow Report 30 June 2011' and contains detailed quarterly cash flow statements, including operating, investing, and financing activities. It includes specific financial figures for the quarter ended 30 June 2011 and year-to-date, as well as notes on payments to directors and compliance statements. The document is over 13,000 characters, indicating it is a substantive financial report rather than a brief announcement. The presence of detailed financial data and the quarterly period covered clearly identify this as a quarterly financial report. The Appendix 4C is a recognized quarterly cash flow report format used by entities admitted on the basis of commitments, consistent with interim or quarterly reporting. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q4 2011
2011-07-28 English
SpringTree facility terminated by mutual consent 2 pages 33.3KB
Capital/Financing Update Classification · 95% confidence The document is a company announcement from Living Cell Technologies Limited dated 26 July 2011. It announces the termination by mutual consent of a Share Purchase and Convertible Security Agreement with SpringTree Special Opportunities Fund, LP. The content focuses on a financing agreement termination and mentions the convertible security retained by SpringTree. There are no financial statements, quarterly or annual results, or detailed financial data presented. The document is a specific update on a financing arrangement rather than a full financial report or earnings release. It is not a report publication announcement since it contains substantive information about the termination of a financing facility. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2011-07-25 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.